Dallas-based Access Pharmaceuticals is reporting that it has made progress with its Cobalamin-targeted drug-delivery program for siRNA therapies. Indeed, it has rebranded its targeted-drug delivery technology as CobaCyte and submitted additional patent applications. We reported back in July that Access Pharmaceuticals and an unnamed partner are testing out a proprietary nanopolymer oral drug--a Trojan Horse that hitches a ride on the body's natural vitamin B12 uptake mechanism. They were testing the product out for oral delivery, rather than injections, of insulin and human growth hormone. It sounds as though delivery of gene-silencing therapeutics is up their sleeve as well. Access release